In Brief
Inflammasomes elicit pyroptosis or cell hyperactivation, with the latter defined as living cells that release IL-1. Zanoni et al. report that CD14 captures distinct lipids within oxPAPC to promote dendritic cell and/or macrophage hyperactivation. Unlike pyroptotic stimuli, oxPAPC lipids promote long-term IL-1 release from cells and non-lethal inflammation in mice.
INTRODUCTION
The study of bacterial lipopolysaccharide (LPS) has provided important insight into the strategies used by the innate immune system to detect infection. Several structurally unrelated LPS receptors exist in mammals, with the best understood being those that promote inflammatory gene expression in macrophages and dendritic cells (DCs) . These receptors include the secreted LPS-binding protein (LBP), the GPI-anchored protein CD14, Toll-like Receptor 4 (TLR4), and its associated factor MD-2 (Kieser and Kagan, 2017; Ostuni et al., 2010) . Upon bacterial encounters, the activities of LBP and CD14 are coordinated to extract LPS from the bacterial cell wall and deliver this lipid to membrane-associated MD-2 and TLR4. This process leads to TLR4 dimerization and signal transduction, which promotes the expression of genes involved in host defense (Tan and Kagan, 2014) . Until recently, it was believed that TLR4 was the sole mediator of cellular responses to LPS (Beutler et al., 2006) , with all other LPS receptors merely serving the aforementioned role of ligand delivery. However, recent work revealed LPS responses that act upstream and independent of TLR4 signaling, or in parallel to TLR4 signaling. Upstream of TLR4 signaling is a set of responses mediated by CD14 that induce TLR4 endocytosis (Zanoni et al., 2011) . In parallel to TLR4 signaling is the LPS-induced assembly of inflammasomes (Hagar et al., 2013; Kayagaki et al., 2013; Shi et al., 2014) . CD14-dependent endocytosis results in the internalization of LPS, CD14, and TLR4 into endosomes, where interferon (IFN)-inducing signaling pathways are activated (Kagan et al., 2008; Zanoni et al., 2011) . Inflammasome activation occurs upon detection of LPS in the cytosol by caspase-11 (caspase 4/5 in humans) (Shi et al., 2014) . Notably, TLR4-deficient cells retain all these activities. Thus, the collection of cellular responses to LPS can be explained only by the independent activities of multiple LPS receptors (Tan and Kagan, 2014) . This view is consistent with the operation of other receptors of the innate immune system that also bind common microbial products (Kieser and Kagan, 2017) .
In addition to detecting microbial products, several innate immune receptors detect self-encoded molecules that are found at the sites of tissue damage (Kono and Rock, 2008; Pradeu and Cooper, 2012) . These self-encoded ligands are referred to as damage-associated molecular patterns (DAMPs), as opposed to their microbial counterparts, known as pathogen-associated molecular patterns (PAMPs). In contrast to our increasing understanding of how PAMPs are detected, numerous questions remain regarding DAMP detection and signaling. It is generally believed that DAMPs operate as endogenous mimetics of PAMPs and should therefore bind similar receptors and induce similar responses (Bianchi, 2007) . In the case of the LPS receptors, the influence of DAMPs on TLR4 signaling is best understood (Schaefer, 2014) . Our knowledge of how DAMPs influence other LPS receptors is limited.
oxPAPC is a mixture of oxidized phosphorylcholine derivatives that are commonly associated with dying cells and are considered LPS-like DAMPs (Imai et al., 2008; Shirey et al., 2013) . ox-PAPC is generated at sites of tissue injury, as these lipids are produced by the spontaneous oxidation of phosphorylcholinecontaining lipids that are present in the plasma membrane of cells (Chang et al., 2004) . oxPAPC is an unusual LPS mimic, in that it activates some LPS receptors but not others (Zanoni et al., 2016) . For example, oxPAPC does not promote TLR4 responses in murine macrophages or DCs. In contrast, oxPAPC interacts with caspase-11. As such, LPS and oxPAPC promote the caspase-11-dependent assembly of inflammasomes and IL-1b release from DCs. The consequences of LPS and oxPAPC interactions with caspase-11 differ, with LPS inducing IL-1b release and pyroptosis. oxPAPC, in contrast, promotes IL-1b release from living DCs. oxPAPC also forms a complex with caspase-1, independent of caspase-11 (Zanoni et al., 2016) , but the consequence of this interaction is unclear. LPS does not interact with caspase-1 (Shi et al., 2014) . The ability of oxPAPC to induce IL-1b release without inducing cell death results in a heightened state of DC activation, dubbed ''hyperactive'' (Zanoni et al., 2016) . DCs are the most professional of all antigen-presenting cells (Mellman et al., 1998) . As compared to DCs that were activated by TLR ligands alone, hyperactive DCs are superior antigen-presenting cells in vivo (Zanoni et al., 2016) . In contrast to DCs, macrophages are unable to become hyperactivated by ox-PAPC (Zanoni et al., 2016) . The features of oxPAPC that permit cell type-specific inflammasome activities are unknown.
In contrast to its ability to hyperactivate DCs that have been pre-exposed to TLR ligands, treatment of naive cells with ox-PAPC blocks subsequent responses to LPS via TLR4 (Bochkov et al., 2002; Erridge et al., 2008) . Thus, depending on the context, oxPAPC is either an activator or inhibitor of inflammation. It is unknown how oxPAPC elicits these disparate activities.
In this study, we found that CD14 acts as a receptor for oxPAPC. CD14 captured and internalized oxPAPC into endosomes, resulting in a depletion of CD14 from the plasma membrane. This inducible CD14 deficiency at the plasma membrane correlated with decreased responses to subsequent exposures to LPS. CD14 endocytosis also delivered oxPAPC into cells, leading to DC hyperactivation and the release of IL-1 family cytokines. Interestingly, we identified specific lipids within oxPAPC that bound CD14 and promoted macrophage hyperactivation. These lipids induced potentiated inflammatory responses, but not death, in murine models of sepsis. These collective data indicate that CD14 is responsible for the pro-and anti-inflammatory activities of oxPAPC. CD14 can therefore be considered a general regulator of host responses to PAMPs and DAMPs. These observations are consistent with the emerging view of CD14 as a transporter associated with the execution of inflammation (TAXI) (Tan et al., 2015) , which captures lipids and receptors as cargo and delivers them to signaling-competent subcellular locations.
RESULTS
oxPAPC Induces a CD14 Deficiency that Diminishes Subsequent Responses to LPS oxPAPC interferes with LPS interactions with CD14 in cell-free experimental systems, suggesting an interaction between these molecules (Bochkov et al., 2002; Erridge et al., 2008) . Within cells, LPS binding by CD14 accelerates the basal endocytosis rate of this receptor and induces the endocytosis of dimerized TLR4 (Tan et al., 2015) . To determine whether oxPAPC engages endogenous CD14 or TLR4, we utilized assays that monitor the inducible dimerization or endocytosis of CD14 and TLR4 by flow cytometry. Endocytosis was monitored using antibodies that detect the entire population of CD14 or TLR4 displayed at the cell surface (Sa2-8 and Sa15-21, respectively). Endocytosis results in the loss of surface staining of these proteins (Zanoni et al., 2011) . TLR4 dimerization was monitored using a monomer-specific TLR4 antibody (MTS510). Loss of MTS510 surface staining indicates an increase in dimer formation and subsequent endocytosis of these dimers (Tan et al., 2015) . Monomer staining at the cell surface indicates the population of receptors that have not interacted with LPS, and therefore are not dimerized. We found that oxPAPC did not induce TLR4 endocytosis, but promoted CD14 endocytosis in immortal bone marrowderived macrophages (Figures 1A and S1A) . oxPAPC had a minimal effect on TLR4 dimerization, with no change in monomer staining observed over the first hour of treatment ( Figure S1A ). oxPAPC-and LPS-induced CD14 endocytosis proceeded normally in TLR4-deficient cells ( Figure 1A ). The surface abundance of CD14 is determined by the antagonistic actions of CD14 endocytosis and resynthesis, and endocytosis is most clearly observed under conditions that prevent the latter (Tan et al., 2015) . Consequently, the extent of oxPAPC-or LPS-induced CD14 endocytosis was enhanced under conditions where translation was blocked with cycloheximide ( Figure S1B ). Cycloheximide treatment did not affect LPS-induced TLR4 internalization or dimerization ( Figures S1C and S1D ). Primary macrophages and bone marrow-derived DCs behaved similar to immortal macrophages, in that oxPAPC promoted CD14 endocytosis but not TLR4 dimerization or endocytosis ( Figure 1B ). Similar to LPS-induced CD14 endocytosis (Zanoni et al., 2011) , ox-PAPC-induced CD14 internalization was sensitive to chemical inhibitors of PLCg (U73122) and Syk (piceatannol) ( Figure 1C ). These data indicate that oxPAPC and LPS promote CD14 endocytosis by similar mechanisms. In contrast, only LPS promotes TLR4 activities that are associated with its signaling functions, such as dimerization and endocytosis. Consistent with these observations, we found that LPS, but not oxPAPC, induced the phosphorylation of TLR4 signaling regulators, including the Map kinases p38 and ERK1/2 and the transcription factors IRF3, STAT1, and the NF-kB p65 subunit ( Figure 1D ).
The oxPAPC-induced endocytosis of CD14 (but not TLR4) created a CD14 deficiency at the plasma membrane. This CD14 deficiency may selectively block TLR4 signaling from endosomes, as CD14 is more important for endosomal signaling events than those occurring at the plasma membrane (Moore et al., 2000; Perera et al., 1997; Zanoni et al., 2011) . Indeed, ox-PAPC-treated cells that were subsequently treated with LPS exhibited defects in TLR4 endocytosis and STAT1 phosphorylation ( Figures 1E, 1F , and S2A), as well as the secretion of type I interferon (IFN) and expression of the IFN-stimulated gene Viperin (Figure S2B and 1F) . All these parameters are classic readouts of TLR4 signaling from endosomes, a process dependent on CD14. LPS-inducible TLR4 dimerization at the plasma membrane was also diminished by oxPAPC pretreatment ( Figure 1E ), but this inhibition did not correlate with defects in TNFa secretion ( Figure S2C ). Thus, oxPAPC-treated cells are selectively defective for TLR4 endocytosis and signaling events from endosomes. The finding that oxPAPC marginally influences signaling events from the plasma membrane eliminates the possibility that, under the conditions used, oxPAPC blocks MD-2 or TLR4 directly, an event that would disrupt all TLR4 signaling events. This ability to dissociate CD14 and TLR4 endocytosis may explain how oxPAPC acts as a TLR4 antagonist.
CD14 Uses the Same Amino Acids to Detect LPS and oxPAPC and Promote Endocytosis As LPS interactions with CD14 promote endocytosis, it was possible that oxPAPC also binds CD14. We therefore determined whether oxPAPC can interact with CD14 and the amino acids within CD14 that are required for these putative interactions. The LPS-binding domain of CD14 is a large hydrophobic pocket that is comprised of four distinct regions in the N terminus of this protein (Figure 2A ; Kim et al., 2005) . We have described CD14 alleles that contain mutations in either one region (1R) or two regions (2R), which retained the ability to form a complex with biotinylated LPS (Tan et al., 2015) . In contrast, mutations of all four regions (4R) in CD14 abolished LPS-binding activity (Tan et al., 2015) . Each of these mutant CD14 alleles encode full-length folded proteins that are transported to the cell surface (Tan et al., 2015) . Interestingly, the 4R mutant was also defective for interactions with a biotinylated oxPAPC analog (oxidized PAPE-N-biotin, oxPNB, referred to here as ''biotin-oxPAPC''), whereas WT, 1R, and 2R CD14 proteins formed a complex with oxPAPC ( Figure 2B ). We reasoned that if LPS and oxPAPC interact with the same residues in the context of WT CD14, then these lipids should compete for CD14 interactions. In support of this idea, we found that excess unlabeled LPS prevented CD14 interactions with biotin-oxPAPC, with an IC 50 of 0.5 mM ( Figure 2C ). Similarly, excess unlabeled oxPAPC prevented CD14 interactions with biotin-LPS, with an IC 50 of 20 mM ( Figure 2C ). These findings further suggest direct interactions between CD14 and the lipids (F) Immortal macrophages were pretreated with indicated concentrations of oxPAPC for 30 min followed by LPS stimulation (10 ng/mL). 4 hr after LPS stimulation, cells were lysed and the activation of the type I IFN pathway were determined by western analysis for p-STAT1 and Viperin. See also Figure S1 .
examined and provide evidence that CD14 may bind preferentially to LPS. Finally, when stably introduced into CD14-deficient immortal macrophages, the 4R CD14 mutant was not internalized in response to LPS or oxPAPC treatments (Figure 2D) . We therefore conclude that CD14 is an oxPAPC receptor, and the same amino acids within CD14 mediate interactions with oxPAPC and LPS. These interactions are important to promote CD14 endocytosis. Interestingly, using the same procedures to monitor CD14 interactions, we found that ox-PAPC also formed a complex with MD-2 ( Figure S2D ). As CD14 acts upstream of MD-2, this interaction cannot explain the actions of oxPAPC on CD14 binding or endocytosis. It is possible that in cells that naturally lack CD14, oxPAPC may bind directly to MD-2 and prevent LPS interactions with the same. But in phagocytes, CD14 must be considered the likely functional target of oxPAPC.
oxPAPC Promotes CD14-Dependent DC Hyperactivation In addition to promoting CD14 endocytosis, oxPAPC induces DC hyperactivation, which is defined by the ability of these cells to release IL-1b while retaining viability (Zanoni et al., 2016) . To determine the relationship between the activities of oxPAPC to promote CD14 endocytosis and promote DC hyperactivation, we examined the requirement of CD14 for oxPAPC-induced IL-1b release. DCs were primed with LPS for 3 hr, which is sufficient time to re-populate the plasma membrane with newly synthesized CD14 (Tan et al., 2015) , and stimulated with oxPAPC. Interestingly, we found that CD14 was required for oxPAPCinduced IL-1b release, as LPS-primed CD14-deficient DCs released minimal IL-1b in response to oxPAPC ( Figure 3A ). Similar results were obtained when the TLR2 ligand Pam3CSK (P3C) was used to prime cells ( Figure 3B ). TNFa secretion was not affected by the loss of CD14 in any of the conditions tested ( Figures 3A and 3B ). To corroborate these findings, we examined IL-18, another cytokine that is released via the actions of inflammasomes. Whereas LPS-primed DCs released IL-18 in response to oxPAPC treatment, CD14-deficient DCs were unable to do so ( Figure 3C ). In contrast, when the inflammasome activator ATP was used as a stimulus, IL-18 release was unaffected by CD14 deficiency ( Figure 3C ). We also observed a requirement for caspase-11 in promoting IL-18 release in response to oxPAPC (Figure 3C) , as shown previously for IL-1b (Zanoni et al., 2016) . Similar results were obtained when we stimulated DCs that were first isolated from the spleens of WT, CD14-deficient, or caspase-11-deficient mice. LPS-stimulated splenic DCs upregulated surface abundance of the co-stimulatory molecule CD86, in the presence or absence of oxPAPC (Figures S3A and S3B) . LPS-primed cells released IL-1b after oxPAPC treatment, by a process dependent on CD14 and caspase-11 ( Figure 3D ). TNFa secretion was unaffected by CD14 or caspase-11 deficiencies in splenic DCs, and ATP stimulations of LPS-primed cells induced IL-1b release independently of CD14 and caspase-11 ( Figure 3D ). (B) oxPAPC binding capacity of the CD14 mutants indicated was determined by biotinylated oxPAPC pull down assay. Lysates of 293T cells expressing the indicated CD14 mutants were incubated with biotinylated oxPAPC (10 mg). CD14-oxPAPC complexes were captured using neutravidin beads. (A and B) WT DCs and CD14-deficient DCs were treated with LPS (1 mg/mL), Pam3CSK (P3C) (1 mg/mL), or oxPAPC (120 mM) or were primed with LPS or P3C for 3 hr and then treated with oxPAPC. 18 hr after LPS (A) or P3C (B) administration, IL-1b and TNFa secretion was measured by ELISA. Means and standard deviations of two independent experiments are shown. (B) Spleen-derived WT DCs, CD14-deficient DCs, and Caspase-11-deficient DCs were treated with LPS (1 mg/mL), ATP (1.5 mM), or oxPAPC (120 mM) or were primed with LPS for 3 hr and then treated with oxPAPC or ATP. 18 hr after LPS administration, IL-1b and TNFa secretion was measured by ELISA. Means and standard deviations of two replicates of one representative experiment of three are shown.
(C) WT DCs, CD14-deficient DCs, and Caspase-11-deficient DCs were treated with LPS (1 mg/mL), oxPAPC (120 mM), or ATP (1 mM) or were primed with LPS for 3 hr and then treated with oxPAPC or ATP. IL-18 was measured by ELISA in the supernatant 18 hr later.
(D) Spleen-derived WT DCs, CD14-deficient DCs, and Caspase-11-deficient DCs were treated with LPS (1 mg/mL), ATP (1.5 mM), or oxPAPC (120 mM) or were primed with LPS for 3 hr and then treated with oxPAPC or ATP. 18 hr after LPS administration, IL-1b (left) and TNFa (right) secretion was measured by ELISA. Means and standard deviations of two replicates of one representative experiment of three are shown. (E and F) WT and CD14-deficient DCs were either primed with LPS (1 mg/mL) for 3 hr and then treated with ATP (1 mM) or were electroporated with LPS (1 mg/mL) or MOCK electroporated. IL-1 (E) and LDH (F) release was monitored 18 hr later. See also Figure S3 .
While oxPAPC and ATP promote inflammasome-dependent cytokine release, the major distinction between these DAMPs is that oxPAPC promotes DC hyperactivation, whereas ATP promotes pyroptosis. CD14 must therefore be considered a selective regulator of DC hyperactivation.
CD14 Does Not Regulate the Priming Phase of Inflammasome Activation
To understand the function of CD14 in DC hyperactivation, we considered the possibility that this receptor regulated cell priming. However, three lines of evidence invalidated this possibility. First, the dose of LPS used (1 mg/mL) bypassed the requirement of CD14 for TLR4-induced cytokine expression, as assessed by analysis of Il1b transcripts and secretion of TNFa ( Figures S4A  and 3A) . Second, P3C-primed DCs also required CD14 for ox-PAPC-induced IL-1b release ( Figure 3B ), even though P3C primes cells via TLR2, independent of CD14 ( Figure S4A ). Finally, ATP-induced IL-1b and IL-18 release was unaffected by CD14 deficiency ( Figures 3C and 3D ), an observation that would not be possible if a priming defect existed.
In other experimental settings, type I IFNs promote caspase-11 expression and/or activation (Broz et al., 2012; Case et al., 2013; Rathinam et al., 2012) . Since CD14 promotes IFN production in response to LPS treatment, as observed by its requirement for Viperin expression ( Figure S4A ), we determined whether recombinant IFNb (rIFNb) could bypass the need of CD14 for oxPAPC-induced IL-1b release. However, rIFNb was unable to restore the ability of oxPAPC to elicit IL-1b release from CD14-deficient cells ( Figure S4B ). In addition, oxPAPC elicited IL-1b release from DCs that were primed with P3C ( Figure 3B ), which did not produce functional type I IFNs, as indicated by a lack of Viperin expression ( Figure S4A ). These experiments therefore indicate that IFN-mediated priming is not necessary for oxPAPC-induced inflammasome activation.
The expression of Caspase-1, Nlrp3 , and Asc mRNAs was largely unaffected by the lack of CD14 in unstimulated or LPS-or P3C-stimulated DCs ( Figure S4C ). However, minor differences in Caspase-1 and Caspase-11 expression were observed in LPS-treated cells ( Figure S4C ). We reasoned that if these differences have functional consequences, then a defect in LPS-induced inflammasome activities should be evident in CD14-deficient DCs. LPS-primed WT and CD14-deficient DCs were electroporated with LPS to examine Caspase-11-and Caspase-1-dependent responses. Notably, WT and CD14-deficient cells responded equally to electroporation of LPS, in terms of IL1b release ( Figure 3E ) and pyroptosis induction, as measured by lactate dehydrogenase (LDH) release ( Figure 3F ). These findings indicate that the amount of Caspase-1 and Caspase-11 present in CD14-deficient cells is sufficient to elicit inflammasomedependent responses. Collectively, these data indicate that CD14 is not required for cell priming. CD14 may therefore have a direct role in promoting inflammasome-dependent IL-1b release in response to oxPAPC.
CD14 Transports oxPAPC into the Cell to Promote DC Hyperactivation
To determine how CD14 promotes inflammasome activities, we considered the endocytosis-promoting activities of this receptor. Since oxPAPC binds to and promotes CD14 endocytosis, we reasoned that CD14 transports oxPAPC into the cell to promote IL-1b release. CD14 may therefore be important to capture oxPAPC from the extracellular space. Consistent with this idea, a fluorescently labeled component of oxPAPC (TopFluor-PGPE) strongly labeled the surface of DCs, as assessed by live-cell confocal microscopy ( Figure 4A ). This labeled lipid was also observed in endosomal vesicles ( Figure 4A ). In contrast, CD14-deficient DCs displayed minimal staining of the plasma membrane by the labeled oxPAPC component ( Figure 4A ). This defect in the capture of extracellular molecules by CD14-deficient cells was specific, as comparable dextran labeling was observed in WT and CD14-deficient cells ( Figure 4A ). Thus, CD14 captures oxPAPC and delivers this lipid into the cell.
We reasoned that if the primary function of CD14 is to deliver oxPAPC into the cell, then it should be possible to bypass the requirement of CD14 by delivering oxPAPC into the cell via alternative means. The transfection reagent DOTAP is a useful tool to deliver inflammatory stimuli directly to endosomes and the cytosol (Honda et al., 2005) . WT and CD14-deficient DCs were therefore primed with P3C and then exposed to DOTAP, in complex with LPS or oxPAPC. As expected, LPS was unable to induce IL-1b release when administered to the extracellular media, but DOTAP-mediated delivery of LPS promoted IL-1b release from WT and CD14-deficient DCs ( Figure 4B ). Interestingly, altering the entry route of oxPAPC into the cells by DOTAP yielded similar results. Whereas extracellular oxPAPC could not elicit IL-1b release from primed CD14-deficient DCs, oxPAPC in complex with DOTAP elicited IL-1b release from CD14-deficient cells, in a Caspase-dependent manner ( Figure 4B ). Cell-associated pro-IL-1b was largely unaffected by these treatments (Figure 4C ). An alternative delivery mechanism can therefore bypass the requirement of CD14 for oxPAPC-induced IL-1b release. These collective data highlight an important role of CD14 in the capture and delivery of oxPAPC into the cell, where inflammasome-mediated DC hyperactivation can occur.
Meta-analysis Reveals Essential and Possibly Redundant Regulators of DC Hyperactivation
To compare the importance of CD14 to that of other regulators of oxPAPC-induced DC hyperactivation, we performed a metaanalysis of multiple genotypes of bone marrow-derived DCs. We plotted the percent of IL-1b release that remained in genetically deficient cells, as compared to WT cells, across 4-16 experiments (depending on genotype) ( Figure 5A ). From this analysis, Asc, Nlrp3, and Caspase-1 emerged as most critical for IL-1b release, with virtually no residual IL-1b release occurring in cells lacking the genes encoding these proteins ( Figure 5A ). These findings are consistent with the functions of these proteins as core components of most inflammasomes. CD14 and Caspase-11 were also validated as important regulators of IL-1b release, but cells lacking these proteins exhibited residual (10%-30%) cytokine release ( Figure 5A ). The residual IL-1b release associated with Caspase-11 deficiency may be explained by the ability to oxPAPC to bind independently to Caspase-11 and Caspase-1 (Zanoni et al., 2016) , perhaps forming distinct complexes that are important for inflammasome assembly. This possibility requires further investigation. The residual cytokine release detected in CD14-deficient DCs, however, is unexplained. To verify the residual IL-1b release associated with CD14 deficiency, we examined the presence of this cytokine in the supernatants of oxPAPC-stimulated DCs by western analysis. Cells lacking CD14 exhibited diminished, albeit incomplete, loss of the processed p17 fragment of IL-1b from the extracellular media ( Figure 5B ). It is possible that CD14-deficient cells may permit some low-level capture of oxPAPC from the extracellular space by macropinocytosis, with functional consequences. Indeed, WT and CD14-deficient DCs displayed comparable macropinocytosis activities, as assessed by the capture of extracellular fluorescent dextrans ( Figures 4A and 5C ). Thus, while it is possible that redundant means of oxPAPC delivery into the cell exist, CD14 is the dominant receptor responsible for inflammasome-dependent DC hyperactivation.
Specific oxPAPC Components Hyperactivate Macrophages and Promote Inflammation In Vivo
Most known inducers of inflammasome responses display activity in DCs and macrophages (Latz et al., 2013) . However, DCs are specifically hyperactivated by oxPAPC; macrophages are not (Zanoni et al., 2016) . To better understand the ability of oxPAPC to induce cell type-specific inflammasome activities, we sought to define the bioactive components of oxPAPC. Our previous work identified the oxPAPC components PGPC (1-palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine) and POVPC (1-palmitoyl-2-(5 0 -oxo-valeroyl)-sn-glycero-3-phosphocholine) as molecules that elicit IL-1b release from LPS-primed DCs (Zanoni et al., 2016) . We found that these lipids were minor components of oxPAPC, individually comprising fewer than 10% of the total lipids present in parental oxPAPC mixture ( Figures S5A and  S5B) . Interestingly, PGPC and POVPC induced the release of IL-1b from LPS-primed macrophages and DCs, whereas ox-PAPC displayed this activity only in DCs ( Figures 6A and 6B) . TNFa secretion in response to all stimulations that included LPS was observed in both cell types ( Figures 6A and 6B) . The cleaved p17 fragment of IL-1b was detected in the extracellular media of LPS-primed DCs and macrophages treated with PGPC and POVPC ( Figures 6C and 6D ), which argues strongly for an inflammasome-dependent event. In contrast, cleaved IL-1b was detected in the extracellular media only of LPS-primed DCs, not macrophages, stimulated with oxPAPC ( Figures 6C and 6D) .
To determine whether PGPC and POVPC induced macrophage hyperactivation, several assays for cell viability were performed. We first performed a visual examination of cell monolayers 24 hr after various stimulations. These studies demonstrated that LPS-primed and ATP-treated WT or CD14-deficient macrophages became rounded and swollen ( Figure S6A ). These cells detached from the tissue culture plate, as a single wash with PBS removed almost all cells ( Figure S6B ), and ATP-treated macrophages that were primed with LPS released LDH (Figure S6C) . These features are hallmarks of pyroptosis. Interestingly, LPS-primed cells that were exposed to oxPAPC or its components maintained cell morphology and adherence and (B and C) WT DCs and CD14-deficient DCs were treated with LPS (1 mg/mL), P3C (1 mg/mL), or oxPAPC (120 mM) or were primed with P3C for 3 hr and then treated with oxPAPC. As indicated, LPS or oxPAPC were complexed with DOTAP before addition to the cell culture. Where indicated, cells where treated with the panCaspase inhibitor zVAD 30 min before addition of the DOTAP/oxPAPC complex to the culture. 18 hr after stimuli administration, secreted (B) or cell-associated (C) IL-1b were measured by ELISA. Means and standard deviations of two independent experiments are shown. See also Figure S4 .
did not release LDH ( Figures S6A-6C ). In addition, macrophages exposed to PGPC or POVPC released increasing amounts of IL1b over 48 hr-an attribute that is consistent with cell viability ( Figure 6B ). DCs behaved similarly in the presence of oxPAPC or its component lipids over 48 hr ( Figures 6A and 6B ). These data therefore support the idea that PGPC and POVPC can induce IL-1b release from living macrophages and DCs. To determine whether the abilities of PGPC and POVPC to induce IL-1b release was a process similar to that induced by oxPAPC in DCs, we determined whether these lipids interact with CD14. This possibility was examined indirectly, by determining whether PGPC or POVPC compete with LPS for access to CD14. We found that excess unlabeled PGPC or POVPC prevented CD14 interactions with biotin-LPS ( Figure 6E) , with an IC 50 of 9.2 mM and 16.8 mM, respectively. As oxPAPC and LPS interactions with CD14 promote endocytosis (Figure 1) , we examined whether PGPC and POVPC induce CD14 endocytosis. PGPC and POVPC induced the rapid endocytosis of CD14 in macrophages and DCs ( Figure 6F ). These collective studies support the conclusion that PGPC and POVPC are ligands for CD14.
To determine the function of CD14 in PGPC-and POVPCinduced IL-1b release, we examined IL-1b release from WT and CD14-deficient macrophages and DCs. LPS-primed macrophages and DCs required CD14 in order to release IL-1b in response to PGPC and POVPC treatments ( Figures 6A and  6B) . We also noted that residual IL-1b release was observed in the absence of CD14 in both cell types, which is an observation similar to what we observed with oxPAPC in DCs (Figures 5A and  5B) . TNFa secretion and cell survival were minimally affected by the absence of CD14 ( Figures 6A, 6B , and S6A-S6C). Similar to oxPAPC in DCs, IL-1b secretion in response to POVPC or PGPC was dependent on NLRP3 and Caspase-1/11 in LPS-primed macrophages ( Figure 6G ).
For these studies, it was critical to eliminate the role of CD14 in cell priming by LPS. Thus, we sought to partially mimic LPS priming by treating cells with a CD14-independent stimulus, P3C, and rIFNb. WT macrophages that were primed in this manner released IL-1b into the extracellular space upon treatment with PGPC and POVPC, and this process was largely dependent on CD14 ( Figures S7A and S7B ). In contrast, CD14 was not required for ATP-induced release of IL-1b from similarly primed cells (Figures S7C and S7D) . Notably, PGPC and POVPC induced the continuous release of IL-1b from primed macrophages, as evidenced by the increase in detectable IL-1b in the extracellular media 96 hr after treatment ( Figure S7A ). In contrast, and as expected, ATP stimulation of primed cells resulted in a short-term release of IL-1b, with no increase of this cytokine between 24 and 96 hr after treatment ( Figures S7C and S7D) . Moreover, visual examination of cells stimulated for 24 hr revealed that POVPCand PGPC-treated macrophages retained morphology ( Figures  S7E and S7F ). These cells released low levels of LDH over this time frame (Figures S7E and S7F) . At this low level, LDH release is not associated with other morphological features of pyroptosis, so the significance of this observation is unclear. ATP treatments, in contrast, were lethal to the cell population, as visual inspection revealed substantial cell rounding and robust LDH release after 24 hr ( Figures S7E and S7F) . Taken together, these data establish that specific components within oxPAPC can engage CD14 to promote IL-1b release from living macrophages.
While our in vitro studies have delineated the abilities of ox-PAPC and its components to hyperactivate phagocytes and not induce pyroptosis, the effects of these different phagocyte activation states in vivo are unclear. At present, we are limited in our ability to directly assess pyroptosis or cell hyperactivation in vivo. However, a strong functional correlation exists between conditions that promote pyroptosis in vitro and those that induce lethal sepsis in vivo (Hagar et al., 2013; Kayagaki et al., 2013) . Indeed, the ability of LPS to kill mice depends on its ability to induce pyroptosis (Hagar et al., 2013; Kayagaki et al., 2013) . As oxPAPC and its components promote IL-1b release but not pyroptosis in vitro, we expected that a similar correlation would exist in vivo, and oxPAPC would induce inflammation but not lethality. To address this possibility, mice were primed (or not) by intraperitoneal injection of LPS for 5 hr and were subsequently challenged by injection with a second dose of LPS, oxPAPC, PGPC, or vehicle ( Figure 7A ). Mice were monitored for viability, and serum cytokines were measured 2 hr and 30 hr after challenge. LPS-primed mice that were challenged with vehicle retained viability throughout the experiment and displayed no or low levels of serum IL-1b, IL-6, and TNFa ( Figures 7B-7G ). In contrast, LPS-primed mice that received a second dose of LPS displayed increased amounts of serum IL-1b, IL-6, and TNFa within 2 hr of challenge ( Figures 7B-7D ). These results are consistent with prior findings (Li et al., 1995) . LPS-primed mice that were challenged with oxPAPC or PGPC for 2 hr also displayed increased amounts of IL-1b, IL-6, and TNFa, as compared to vehicle-challenged mice ( Figures 7B-7D ), although each challenge yielded different amounts of each cytokine. Comparable amounts of IL-6 were found in the serum of LPS-, oxPAPC-, and PGPC-injected mice 2 hr after challenge, whereas each lipid induced different amounts of IL-1b or TNFa release ( Figures 7B-7D) . Interestingly, whereas LPS-primed mice that were challenged with LPS all died within 30 hr, no loss of animal viability was observed in LPS-primed mice that were challenged with oxPAPC or PGPC ( Figure 7E ). 30 hr after challenge, ox-PAPC-and PGPC-treated mice still displayed increased serum cytokines, although each challenge resulted in different cytokines being detected ( Figures 7F and 7G ). These collective results demonstrate that conditions that promote pyroptosis in vitro (double LPS treatments) lead to lethal sepsis in vivo, whereas conditions that promote phagocyte hyperactivation in vitro (LPS and oxPAPC treatments) lead to inflammation (but not death) in vivo. These findings support the idea that phagocyte hyperactivation is a bona fide cell activation state that can be observed in multiple experimental settings.
DISCUSSION
In this study, we explored how oxPAPC can have the opposing activities of (1) interfering with TLR4 signaling to prevent inflammatory responses and (2) hyperactivating cells to promote inflammation. Our studies demonstrate that CD14 is a central regulator of both activities.
We found that CD14 bound oxPAPC and captured these lipids from the extracellular space. Upon capture, CD14 and oxPAPC were delivered into the cell via endocytosis. oxPAPC-induced CD14 endocytosis diminished the abundance of CD14 at the plasma membrane, creating an inducible CD14 deficiency that rendered cells poorly responsive to subsequent encounters with LPS. Interestingly, we observed a similar behavior of the anti-inflammatory LPS derived from Rhodobacter spheroides (Tan et al., 2015) , which is the prototype lipid of the commercialized TLR4 antagonist Eritoran. When administered to naive cells, oxPAPC and R. spheroides LPS promoted CD14 endocytosis, but not TLR4 endocytosis, thus creating a functional CD14 deficiency. It therefore appears that a common means by which TLR4 antagonists operate is by the inducible removal of CD14 from the plasma membrane.
Our prior work highlighted how CD14 functions to transport LPS and TLR4 to signaling-competent regions of the cells, thus revealing this protein as a TAXI (Tan et al., 2015) . The findings reported in this study are consistent with this idea and expand the function of CD14 beyond its role as a TAXI for LPS and TLR4. Rather, CD14 must now be considered a general TAXI for inflammatory lipids derived from the host or microbe. Furthermore, the endocytosis-promoting activities of CD14 must now be considered in a context of broader significance than simply regulating TLR4 activities. In the case of oxPAPC, for example, CD14 captured and delivered this DAMP into the cell to promote IL-1b release. CD14 therefore represents the earliest-acting regulator of DC hyperactivation, serving as an ox-PAPC receptor. These conclusions, however, do not rule out the possibility that other oxPAPC receptors operate to capture this lipid from the extracellular media, with functionally important consequences. Indeed, other receptors may explain the residual oxPAPC-induced IL-1b release that is observed in CD14-deficient cells.
That CD14 acts as a functional receptor of oxPAPC is notable, because there are several examples of extracellular molecules that promote inflammasome assembly and IL-1b release. However, it is unclear how many of these molecules are captured by cells. One thoroughly characterized means by which extracellular molecules are delivered into the cell to promote inflammasome activities is via the actions of bacterial pore-forming toxins or secretion systems. Our finding that CD14 is an oxPAPC receptor that is required for DC hyperactivation therefore provides insight into the earliest stages of the inflammatory response. It remains unclear how oxPAPC is delivered from endosomes into the cytosol. We note several other immunological processes involve such a transport event, such as the transport of extracellular antigens to the MHC class I machinery (Cruz et al., 2017) , (E) Lysates of 293T cells expressing CD14 were pretreated with indicated concentrations of POVPC or PGPC for 30 min and then incubated with biotinylated LPS (1 mg). CD14-LPS complex was captured using neutravidin beads. The amount of CD14 retained by LPS in the presence of POVPC or PGPC was determined by western analysis. Representative blots from at least two independent experiments were shown. (F) WT DCs or macrophages were treated with oxPAPC (120 mM), POVPC (120 mM), and PGPC (120 mM) for indicated time periods. Surface levels of CD14 from DCs or macrophages were measured by flow cytometry. Line graphs with standard deviations represent the average of duplicate readings from one representative experiment out of three. (G) WT, Caspase1/11 double-deficient, and NLRP3-deficient macrophages were treated with LPS or not for 3 hr, and then treated, or not, with oxPAPC (120 mM), POVPC (120 mM), PGPC (120 mM), and DMPC (120 mM). IL-1b secretion was measured by ELISA. Means and standard deviations of two replicates of one representative experiment out of three are shown. See also Figure S6 . and the delivery of peptidoglycan fragments to NOD1 and NOD2 in the cytosol (Philpott et al., 2014) . Our knowledge of how endosomal molecules are transported to the cytosol remains limited.
The identification of specific lipids within oxPAPC that hyperactivated macrophages is also notable, as the heterogenous ox-PAPC mixture can hyperactivate only DCs (Zanoni et al., 2016) . We found that, similar to oxPAPC, PGPC and POVPC competed with LPS for access to CD14 in vitro, promoted CD14 endocytosis, and promoted IL-1b release from living macrophages, by a CD14-and inflammasome-dependent process. It is unclear why PGPC and POVPC were able to hyperactivate macrophages only in isolation, and not when present within the heterogenous oxPAPC mixture. This observation may be explained by the fact that macrophages contain more degradative endo-lysosomes than DCs (Delamarre et al., 2005) . As PGPC and POVPC represent fewer than 10% of the total lipids within oxPAPC (Figure S5) , it is possible that high concentrations of these lipids are necessary to allow any bioactive lipids to escape macrophage endosomes and promote inflammasome-dependent phagocyte hyperactivation.
A notable feature of hyperactive cells is their unusual ability to maintain viability while releasing IL-1 family cytokines. Evidence supporting this conclusion is several-fold, as treatment of cells with oxPAPC or its individual components promoted the release of IL-1, but not LDH. These cells also maintained plasma membrane integrity and maintained mitochondrial activity (Zanoni et al., 2016) . Furthermore, as shown in this study, these cells maintained morphology and the ability to attach to tissue culture plates and release IL-1 continuously over the course of several days. In contrast, pyroptotic cells (which have been treated with ATP or transfected with LPS) released LDH and lost plasma membrane integrity, morphology, adhesiveness, and mitochondrial activity. These cells were able to release IL-1b only over a short time frame (hours). Thus, inflammasomes can induce two opposing cell fate decisions-pyroptosis and cell hyperactivation.
Is it possible that non-pyroptotic death pathways contribute to the long-term IL-1b release that typifies the hyperactive state of phagocytes? At the population level, the answer must be yes. It is formally possible that some of the released IL-1b results from apoptotic programs that are induced 24-96 hr after stimulation. However, these putative programs cannot explain the finding that POVPC and PGPC promote inflammasome-dependent events that cleave pro-IL-1b, in the absence of any notable features of pyroptosis. Live single cell imaging may be necessary to explore these possibilities fully.
In murine models of inflammatory sepsis, the opposing cell fate decisions of pyroptosis and hyperactivation have profound consequences, as conditions that promote pyroptosis in vitro lead to lethal inflammatory sepsis in vivo. In contrast, conditions that promote cell hyperactivation in vitro lead to inflammation but not lethality in vivo. These findings are consistent with the idea that inflammatory cytokine production must be coupled with pyroptosis in order to induce lethality in response to LPS injections of mice. These findings further demonstrate that the state of cell hyperactivation exists in vitro and in vivo. It is also worth noting that oxPAPC is not unique in its ability to hyperactivate cells. Recent work has identified the N-acetyl glucosamine fragment of bacterial peptidoglycan as being able to elicit IL-1 release from living macrophages (Wolf et al., 2016) , and LPS is sufficient to induce the same response in human and pig monocytes (Gaidt et al., 2016) . Thus, select DAMPs and PAMPs have the ability to hyperactivate phagocytes. These new findings, coupled with our demonstration that hyperactivating stimuli (LPS and oxPAPC treatments) are superior inducers of adaptive immunity than activating stimuli (LPS alone) (Zanoni et al., 2016) support the importance of understanding this newly defined aspect of phagocyte biology.
The collection of information available allows us to propose a working model of how oxPAPC and its component lipids operate in vivo. We propose that oxPAPC is an inhibitor of TLR4 signaling, but only when cells are pre-exposed to these lipids-before they encounter LPS. oxPAPC exposures in the absence of LPS may mimic environments associated with sterile tissue injury. Under these conditions, CD14 endocytosis after interactions with oxPAPC may render cells less responsive to any TLR4-activating DAMPs that are present in the damaged tissue. This response limits the risk of autoimmunity. Under conditions of oxPAPC and LPS co-exposure, TLR4 signaling is not blocked. Rather, oxPAPC enhances inflammatory activities by inducing an inflammasome-dependent state of cell hyperactivation. We speculate that conditions of oxPAPC and LPS co-exposure may mimic the environment associated with virulent pathogenic encounters, where tissue damage and PAMPs are abundant. Under these conditions, a hyperactive cell state may be important to fight virulent pathogens. This work therefore provides a mandate to consider the role of CD14 and other regulators of phagocyte hyperactivation in controlling the activities of inflammatory lipids in the host and microbial world.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
Western analysis
For western analysis, immortal macrophages (5x10 6 ) were stimulated with ligands for the times indicated, and lysed in 700 mL of lysis buffer containing 1% NP-40, 50mM Tris-HCl (pH 7.4), 150mM NaCl. Protease inhibitors and phosphatase inhibitors were added just prior to cell lysis. Immunoblotting was performed using standard techniques. For measurement of processed IL-1b released into the extracellular space, cell culture supernatants from DCs were collected. IL1b was captured with a biotinylated IL-1b antibody, and subsequently isolated via streptavidin beads for 2 hr on a nutator at 4 C. After washing, samples were eluted in SDS loading buffer and separated by SDS-PAGE. Captured IL-1b was detected by western analysis. NLRP3 and Pro-IL-1b in the cell lysates were determined on a separate blot. Actin was probed as loading control.
Flow cytometry
Immortal macrophages, primary bone marrow derived macrophages and DCs or splenic DCs (0.5x10 6 ) of the indicated genotypes were treated with E.coli LPS and/or oxPAPC for the indicated time points at 37 C. Cells were then washed with 1 mL cold PBS and stained for appropriate antibodies on ice for 20 to 30 min. 2% mouse serum or rat serum were used as the blocking reagent to reduce non-specific binding of the antibodies. The stained cells were then washed with 1ml cold PBS and resuspended in 200 mL PBS. Staining of the surface receptors was analyzed with BD FACSCanto II. The mean fluorescence intensity (MFI) of CD14 and TLR4 from unstimulated or stimulated cells were recorded. The percentage of surface receptor staining at indicated time points, which is the ratio of the MFI values measured from the stimulated cells to those measured from the unstimulated cells, was plotted to reflect the efficiency of receptor endocytosis. For measuring the extent of TLR4/MD-2 dimerization, the percentage of TLR4/MD2 dimer was calculated by 100%-the percentage of TLR4/MD-2 monomer. The percentage of the TLR4/MD-2 monomer was determined by the ratio of the MFI values (obtained from MTS510 antibody staining) of the stimulated cells to those of the unstimulated cells.
LPS Electroporation
For LPS electroporation into LPS-primed WT and CD14 macrophages, the Neon transfection system (Life Technologies) was used with 10^6 primed-cells plus 1 mg LPS per chamber condition with the following program (Voltage: 1400 V; Width: 20 ms; Pulses: 2 pulses). Electroporated cells were immediately plated into pre-warmed antibiotic-free complete RPMI and then cultured for 24 hours.
Microscopy imaging of cell morphology and live cell imaging
To determine cell morphology after inflammasome stimulation, macrophages were seeded in 12-well plates (0.5 3 10 6 /ml per well) and were subjected to treatments indicated. For static image capture, a Nikon Eclipse TS100 microscope was used with 20 x or 40 x magnification. Images were processed with the ''NIS-Elements F'' software. Representative images were chosen from at least three randomly chosen fields from one experiment out of two independent experiments. For live cell imaging, DCs seeded into a 35 mm glass bottom dish (Ibidi) were incubated with 5 mg/ml TopFluor-PGPE (Avanti Polar Lipids, inc.) and 200 mg/ml Alexa568-labeled dextran (Thermo Scientific) for one hour. Images were acquired with a Zeiss Axiovert 200M inverted confocal microscope and the level of single cell fluorescent intensity for the two channels was analyzed using ImageJ software (NIH).
In vivo challenges Female mice aged 8 weeks were primed via intraperitoneal (i.p.) injection with 1 mg/kg E. coli LPS or vehicle control for 5 hours. Mice were then challenged via i.p. injection with the stimuli indicated. The mice were monitored for 30 hours for survival and serum blood samples were collected at 2 hours and 30 hours post-challenge for cytokine analysis. All animal procedures were approved by IACUC.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical significance for experiments with more than two groups was tested with One way Anova and Tukey multiple comparison tests were performed. Two Way ANOVA with Tukey multiple comparison test was used to analyze kinetic experiments. When comparisons between only two variables were made, unpaired two tailed t test was used to assess statistical significance. Adjusted p values were calculated with Prism7 (Graphpad) or with Excel. Asterisk coding, also indicated in figure legends, is depicted as follows: *p % 0.05; **p % 0.01; ***p % 0,001; ****p % 0,0001.
